Table 1.

Clinical and nerve excitability data, oxaliplatin dosages, presence of neuropathic symptoms, and reason for oxaliplatin cessation for each patient

Single dose range (mg)Cumulative dose (mg)Chronic neuropathyHighest RRPInitial RRP elevationNCI-CTCReason for cessation of oxaliplatin
#1 (64)110-140 (15)1,820Yes (10th cycle)4.84Cycle 31Neurotoxicity
#2 (63)180 (6)1,080No3.080Disease progression
#3 (52)110-170 (9)1,250Yes (9th cycle)4.09Cycle 63Neurotoxicity
#4 (63)125-160 (8)1,175Yes (4 wk post)6.48Cycle 33Completed therapy
#5 (74)190 (2)380No3.160Declined further therapy
#6 (71)123-162 (10)1,269Yes (9th cycle)4.02Cycle 32Neurotoxicity
#7 (74)135-175 (10)1,470Yes (2 wk post)5.05Cycle 33Disease quiescent
#8 (57)180-220 (4)840No3.980Disease progression
#9 (54)177-236 (6)1,593No2.940Completed therapy
#10 (57)100-132 (9)1,128No3.820Disease progression
#11 (70)100-180 (13)2,020Yes (9th cycle)5.75Cycle 23Disease progression
#12 (54)250 (7)1,750Yes (7th cycle)3.943Neurotoxicity
#13 (76)100-150 (12)1,470No3.640Completed therapy
#14 (42)105-140 (10)1,190Yes4.06Cycle 22Completed therapy
#15 (49)136 (12)1,632No3.140Completed therapy
#16 (24)150-188 (10)1,690No2.820Completed therapy
#17 (68)96-157 (8)1,158No3.970Disease quiescent
#18 (72)155 (9)1,395No3.770Disease progression
#19 (22)165 (10)1,650No3.850Completed therapy
#20 (73)140-175 (9)1,470Yes3.533Neurotoxicity
#21 (60)90-150 (8)860No2.90Disease progression
#22 (63)110-170 (7)975No3.140Completed therapy
  • NOTE: Maximal single infusion dosage is calculated using body surface area to correspond to a dosage of 100 mg/m2 and the total number of cycles of treatment is indicated in brackets after range of single infusion dose. Chronic symptoms are those which were present at the time of the first review following completion of oxaliplatin treatment. The neurosensory scale of the National Cancer Institute Common Toxicity Criteria (NCI-CTC; version 1) was used with the following grading system (21): 0, no neuropathy; 1, mild paresthesias, loss of deep tendon reflexes; 2, mild or moderate objective sensory loss or moderate paresthesias; and 3, severe objective sensory loss or paresthesias that interfere with function. The number of cycles after which chronic symptoms were first noted is given in brackets. Two patients (#4 and #7) developed chronic symptoms 4 and 2 weeks after the completion of oxaliplatin therapy respectively. Relative refractory period (RRP) duration was >4 ms in 78% patients with chronic neuropathy and the cycle at which this change was first noted is shown. Two patients (#5 and #10) died 4 to 6 weeks after completion of oxaliplatin therapy. Although nerve conduction studies were not undertaken, there were no clinical signs of neuropathy.